Lightspeed Seeks to Exclude Prior $13M Verdict from Upcoming IP Trial

Ahead of a fast-approaching jury trial, point-of-sale and e-commerce organization Lightspeed has proposed a legal strategy aimed at preventing the potential utilization of past litigation victories by their opposition. Specifically, the Pennsylvania-based patent company is being asked not to reference a previous $13M verdict victory that took place in Texas federal court. According to Law360’s…

Read More

United Therapeutics v. Liquidia Technologies: Analyzing Inherent Anticipation in Patent Law Developments

In the complex realm of patent law, the case of United Therapeutics Corporation v. Liquidia Technologies, Inc. offers some critical insights. This case, an appeal and cross-appeal originating from a District of Delaware decision, touches on several key issues relating to patent infringement and validity. The case centers around the status of several different claims…

Read More

Congressional Patent Bills Poised to Reshape Infringement Litigation Landscape

Recent developments in Congress could potentially reshape the patent litigation landscape, with two bills recently introduced seeking to reform patent eligibility and change procedures for litigating patent invalidity. These developments may require legal professionals involved in patent litigation to recalibrate strategies and anticipate the potential implications of such legislative changes on infringement litigation. The first…

Read More

Pharmaceutical Patent Litigation: The Balance Between Safety, Efficacy, and Innovation

In a recent case, United Therapeutics Corporation v. Liquidia Technologies, Inc., there was a discussion by the Federal Circuit on July 24 concerning the necessity for safety and efficacy within pharmaceutical method claims to be sufficiently enabled and backed by written description. This case was sparked when Liquidia Technologies filed a new Drug Application for…

Read More

USPTO Director Overturns PTAB Decision, Rekindling Hormonal Disorder Treatment Innovation

In a recent development, the director of the U.S. Patent and Trademark Office (USPTO) has overturned a Patent Trial and Appeal Board (PTAB) decision that declined to re-evaluate a biotech firm’s patent pertaining to a hormonal disorder treatment. The reversal came on Friday, and it was a significant move by Andrei Iancu, the USPTO Director….

Read More

PTAB Emphasizes Degree of Investment in Parallel Proceedings for Fintiv Factor 3 Decision

In a relevant recent development, the PTAB (Patent Trial and Appeal Board) granted the institution of an Inter Partes Review (IPR) in light of several parallel district court proceedings regarding the same patent. The Board was not persuaded by the Patent Owner’s argument that the petitioner’s “conflicting” stances regarding claim construction within the district court…

Read More

AI and IP: Navigating the Complex Intersection of Artificial Intelligence and Intellectual Property Rights

Artificial Intelligence (AI) tools, ranging from text and image generators to music and software code marvelling utilities, have seen a significant proliferation recently. However, their integration with Intellectual Property (IP) has been the subject of intense discussion in legal circles. One of the key focal points of these debates circles around whether works of art…

Read More

Apple and Samsung Patent Lawsuits Highlight Jurisdictional Discrepancy in Texas Court

In a recent patent lawsuit involving technology giant Apple and its South Korean competitor Samsung, Western District of Texas Judge Alan Albright demonstrated a contrasting decision in the courtroom. Significant to the legal professionals and corporations worldwide, this occurrence casts useful insights into the current justice system’s decision-making process with respect to patent suits. Apple…

Read More

Bankrupt Automaker Lordstown Motors Attracts 13 Potential Bidders Amid IP Battle

Lordstown Motors, the bankrupt electric automaker, revealed to a Delaware judge that it had received expressions of interest from 13 potential bidders as part of its Chapter 11 sale process. Despite a forthcoming trial over trade secret claims, which has undoubtedly caused estrangement amongst some potential suitors, the judge approved the majority of Lordstown’s proposed…

Read More

PacBio Patent Infringement Case Transferred from Delaware to California

The patent infringement case against biotechnology firm Pacific Biosciences of California Inc. has been moved from a Delaware federal court to California. According to the judgement, there were insufficient reasons to support maintaining the case proceedings in Delaware. Pacific Biosciences of California Inc., commonly known as PacBio, is a biotechnology company that’s profusely involved in…

Read More

Federal Circuit Delivers Pivotal Ruling in United Therapeutics v. Liquidia Pharmaceuticals Patent Case

In the continually evolving arena of patent law, the third week of July 2023 has seen pivotal advancement in patent cases adjudicated by the Federal Circuit. One such central case involved the United Therapeutics Corp. and Liquidia Technologies, Inc. (Nos. 2022-2217, 2023-1021, Fed. Cir. (D. Del.) July 24, 2023). The case merits attention due to…

Read More